Comparison · NCT01553149-9546bb8c
Arm I (Low-dose Lenalidomide) vs Arm II (High-dose Lenalidomide): Number of Patients With Toxic Events After 2 Dose Reductions
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Low-dose Lenalidomide) vs Arm II (High-dose Lenalidomide): Number of Patients With Toxic Events After 2 Dose Reductions. Trial comparisons, record NCT01553149-9546bb8c. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01553149-9546bb8c
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0541 | 0.015 | 0.177 | wilson | |
| Risk in group 2 | 0.432 | 0.287 | 0.591 | wilson | |
| Risk difference, group 1 minus group 2 | -0.378 | -0.542 | -0.188 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.125 | 0.0309 | 0.506 | log | |
| Odds ratio, group 1 over group 2 | 0.075 | 0.0157 | 0.359 | log | |
| Number needed to treat, for one fewer participant with the outcome on Arm I (Low-dose Lenalidomide) than on Arm II (High-dose Lenalidomide) | 2.64 | 1.85 | 5.33 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Low-dose Lenalidomide) | Patients receive low-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.~Lenalidomide: Given PO~Pharmacological Study: Correlative studies | 2 | 37 | OG000 |
| Group 2 | Arm II (High-dose Lenalidomide) | Patients receive high-dose lenalidomide PO QD on days 1-21. Treatment repeats every 28 days for up to 26 courses in the absence of disease progression or unacceptable toxicity.~Lenalidomide: Given PO~Pharmacological Study: Correlative studies | 16 | 37 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Toxic Events After 2 Dose Reductions
- Description
Number of patients who have an additional significant toxicity coded using Common Terminology Criteria for Adverse Events Version 5.0 after experiencing two dose reductions from their assigned treatment dose.
- Time frame
- While receiving protocol therapy up to 3 years after study enrollment
- Population
- Only eligible patients are considered in the analysis of this outcome measure
Source ClinicalTrials.gov
Trial
- Title
- Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma
- NCT number
- NCT01553149
- Phases
- PHASE2
- Conditions
- Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma, Recurrent Childhood Visual Pathway Glioma
- Interventions
- Lenalidomide, Pharmacological Study
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2021-11-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01553149?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01553149-9546bb8c